Author

Charu Kaiwar

Children's Hospital ColoradoORCID 0000-0002-0862-9538Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:benchmark study· 1 Research Focus:benchmarking· 1 Research Focus:database / resource· 1 Organism:human· 1 Approach:statistical model· 1 Research Focus:variant effect prediction· 1 Assay:whole-exome sequencing· 1

Frequent Co-Authors

Ana Lisa Taylor TavaresiD· 2 shared Annemieke M Aartsma-RusiD· 2 shared Bushra HaqueiD· 2 shared Danique BeijeriD· 2 shared David CheerieiD· 2 shared Emma Sherrill· 2 shared Gregory CostainiD· 2 shared Logan NewtoniD· 2 shared

Activity by Year

2025-2025 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 45 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersGenetic & Genomic Medicine

Ana Lisa Taylor TavaresORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Screening rare genetic diagnoses for amenability to bespoke antisense oligonucleotide therapy development: a retrospective cohort study

David Cheerie, Marlen C. Lauffer, Logan Newton, Kimberly Amburgey, Danique Beijer, Bushra Haque, Brian Thomas Kalish, Margaret M. Meserve, Rachel Youjin Oh, Amy Y. Pan, Miriam S. Reuter, Michael J. Szego, Anna Szuto, Ana Lisa Taylor Tavares, Annemieke M Aartsma-Rus, , Evgueni A. Ivakine

The paper estimates the proportion of genetic diagnoses in a pediatric cohort that are amenable to antisense oligonucleotide therapy, finding 4.9% eligible or likely eligible.

Genetics in Medicine · Oct 11, 2025Peer-reviewedGenetic & Genomic Medicine

Consensus guidelines for eligibility assessment of pathogenic variants to antisense oligonucleotide treatments

David Cheerie, Margaret M. Meserve, Danique Beijer, Charu Kaiwar, Logan Newton, Ana Lisa Taylor Tavares, Aubrie Soucy, Emma Sherrill, Stefanie Leonard, Stephan Sanders, Emily J. Blake, Nour M. Elkhateeb, Aastha Gandhi, Nicole Si Yan Liang, J. Morgan, , Marlen C. Lauffer

The paper presents consensus guidelines for assessing pathogenic variants' eligibility for antisense oligonucleotide treatments, including classification criteria and considerations for different therapeutic approaches.

The American Journal of Human Genetics · Mar 26, 2025Peer-reviewedGenetic & Genomic Medicine